4.7 Article

Integrated Metabonomics and Network Pharmacology to Reveal the Action Mechanism Effect of Shaoyao Decoction on Ulcerative Colitis

期刊

DRUG DESIGN DEVELOPMENT AND THERAPY
卷 16, 期 -, 页码 3739-3776

出版社

DOVE MEDICAL PRESS LTD
DOI: 10.2147/DDDT.S375281

关键词

metabolomics; UPLC-Q-TOF-MS; network pharmacology; Shaoyao decoction; ulcerative colitis

资金

  1. Zhejiang Province Traditional Chinese Medicine Science and Technology Project
  2. Zhejiang Traditional Chinese Medicine Administration
  3. Zhejiang Province Natural Science Foundation
  4. [Z2021ZQ042]
  5. [2020ZZ010]
  6. [LY21H270007]

向作者/读者索取更多资源

This study investigated the mechanism of Shaoyao decoction (SYD) in the treatment of ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) using metabolomics and network pharmacology. The results showed that SYD effectively improved symptoms and ameliorated intestinal mucosal damage and metabolic disorder in DSS-induced UC mice. The mechanism of action mainly involves sphingolipid metabolism, PI3K/AKT-mTOR signaling pathway, and S1P3 pathway.
Background: Traditional Chinese medicine (TCM) has the advantage of multi-component and multi-target, which becomes a hot spot in the treatment of numerous diseases. Shaoyao decoction (SYD) is a TCM prescription, which is mainly used to treat damp-heat dysentery clinically, with small side effects and low cost. However, its mechanism remains elusive. The purpose of this study is to explore the mechanism of SYD in the treatment of mice with ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) through metabolomics and network pharmacology, and verify through molecular docking and immunohistochemistry, so as to provide a scientific basis for the role of SYD in the treatment of UC. Materials and Methods: Firstly, DSS-induced UC models were established and then untargeted metabolomics analysis of feces, livers, serum and urine was performed to determine biomarkers and metabolic pathways closely related to the role of SYD. Besides, network pharmacology was applied to screen the active components and UC-related targets, which was verified by molecular docking. Finally, metabonomics and network pharmacology were combined to draw the metabolite-pathway-target network and verified by immunohistochemistry. Results: Metabolomics results showed that a total of 61 differential metabolites were discovered in SYD-treated UC with 3 main metabolic pathways containing glycerophospholipid metabolism, sphingolipid metabolism and biosynthesis of unsaturated fatty acids, as well as 8 core targets involving STAT3, IL1B, IL6, IL2, AKT1, IL4, ICAM1 and CCND1. Molecular docking demonstrated that the first five targets had strong affinity with quercetin, wogonin, kaempferol and baicalein. Combined with metabolomics and network pharmacology, sphingolipid signaling pathway, PI3K/AKT-mTOR signaling pathway and S1P3 pathway were identified as the main pathways. Conclusion: SYD can effectively ameliorate various symptoms and alleviate intestinal mucosal damage and metabolic disorder in DSS induced UC mice. Its effect is mainly related to sphingolipid metabolism, PI3K/AKT-mTOR signaling pathway and S1P3 pathway.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据